Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research units
Publications
Datasets
Search by expertise, name or affiliation
The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
Antonio Anzueto
, Robert Wise
, Peter Calverley
, Daniel Dusser
, Wenbo Tang
, Norbert Metzdorf
, Ronald Dahl
Division of Pulmonary Diseases
Research output
:
Contribution to journal
›
Article
›
peer-review
19
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Tiotropium Bromide
100%
Respimat
100%
Forced Expiratory Volume
46%
Deterioration
33%
Spirometry
26%
Patient
26%
Inpatient
20%
Chronic Obstructive Pulmonary Disease
13%
Forced Vital Capacity
13%
Group Trial
13%
Group Therapy
6%
Combination Therapy
6%
Smoking
6%
Airway Obstruction
6%
Disease Severity
6%
Bronchodilating Agent
6%
Analysis
6%
Arm
6%
Therapeutic Procedure
6%
Lung
6%
Amaurosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
13%
Combination Therapy
6%
Bronchodilating Agent
6%
Airway Obstruction
6%
Disease Severity
6%
Blindness
6%